Precision Oncology Program for Prostate Cancer

Full Title:
POPCaP Authorization Act of 2026

Summary#

This bill tells the Department of Veterans Affairs (VA) to set up a precision oncology program focused on prostate cancer. It creates a network of Centers of Excellence, a central Program Leadership team, a uniform genetic sequencing system, a prostate cancer registry, and rules for clinical trials and reporting. The stated goal is to coordinate care, genetic testing, and research for veterans with prostate or related genitourinary cancers.

Key changes:

  • Creates a new VA program called the Precision Oncology Program for Cancer of the Prostate (POPCaP).
  • Designates 28 initial Centers of Excellence (listed in the bill) and requires at least 21 centers overall, with at least one in each Veterans Integrated Service Network and at least seven with genitourinary programs.
  • Requires Centers to do genetic sequencing, join a telemedicine tumor board, keep registry data, run biomarker-specific trials, offer metastasis biopsy capability, and provide travel support to veterans for studies.
  • Establishes a Program Leadership team based at the Seattle VA Medical Center (to remain a center until at least 2033) with Executive, Clinical, and Research Directors and several coordination duties.
  • Authorizes $15,500,000 per year for fiscal years 2027–2029 to carry out the program.
  • Sets timelines: program must be set up within 180 days of enactment; an implementation plan is due within 60 days.

What it means for you#

  • Veterans with prostate cancer or other genitourinary cancer

    • If you are enrolled in the VA patient enrollment system and have a qualifying diagnosis, you will be eligible to join the program.
    • You could get genetic sequencing (testing of tumor DNA), access to biomarker-specific clinical trials, telemedicine tumor board reviews, and travel support to attend studies.
    • Your clinical and genetic data may be entered in a VA prostate cancer registry and data repository.

  • VA medical centers and clinicians

    • Selected Centers must meet staffing minimums (medical oncologist, interventional radiologist, urologist, radiation oncologist, pathologist, and two full-time research staff) and build capabilities such as metastasis biopsy and trial operations.
    • Centers must participate in monthly teleconferences and at least three in-person meetings annually with Program Leadership.

  • Researchers and trial sponsors

    • The Program Leadership team will coordinate trial engagement, help design hybrid decentralized trials (remote coordination and data management), and maintain a central registry to support research.
    • Centers are expected to develop and run biomarker-specific and industry-sponsored precision oncology studies.

  • VA administration

    • Must create and run the program, maintain a uniform sequencing platform, produce annual reports with specific metrics (including five-year survival rates), and perform periodic performance reviews of Centers starting in 2030.

  • General public

    • The bill names 28 initial Centers of Excellence across multiple states. The program aims to improve coordination of prostate cancer research and care within the VA system.

Expenses#

Estimated public cost: The bill authorizes $15,500,000 per year for fiscal years 2027, 2028, and 2029 to carry out the program.

  • Direct federal authorization: $15.5 million per year (FY2027–FY2029) is specifically authorized.
  • Other costs not detailed: The bill requires Centers to add staff, build biopsy capability, run trials, set up a sequencing platform, and maintain a registry. The text does not provide estimates for those costs beyond the three-year authorization.
  • Funding protections: The bill prevents the VA from removing prostate-cancer-related staff or reducing funding at currently designated Centers (refers to a specific statutory section) below amounts in effect on January 1, 2023, until January 1, 2030. This could limit VA budget changes but no dollar amount is given.
  • Implementation plan: VA must submit a plan within 60 days that includes anticipated funding levels for a ten-year period; that plan may clarify longer-term costs (not included in the bill text).

No publicly available information beyond the bill text on total expected long-term costs or savings.

Proponents' View#

  • The bill appears intended to improve care and research for veterans with prostate and related cancers by coordinating genetic testing, trials, and clinical care across VA centers.
  • Supporters may argue the program could increase veteran access to precision (genetic-based) treatments and clinical trials.
  • Creating a uniform genetic sequencing platform and a shared registry could make it easier to match veterans to biomarker-specific studies and to track important genetic mutations and outcomes.
  • The Program Leadership team is designed to help smaller VA centers run trials and connect with industry and national research efforts.
  • The bill includes protections to keep existing prostate-cancer staff and funding in place at designated Centers through 2030, which could preserve services during program rollout.

Opponents' View#

  • One concern is that the bill authorizes funding for only three fiscal years (2027–2029) and does not specify ongoing funding beyond 2029; it is unclear whether $15.5 million per year is sufficient to cover the program’s requirements across many Centers.
  • The bill requires substantial new capabilities at Centers (sequencing, biopsies, trial infrastructure, registry), but it does not provide detailed cost estimates or explain how all costs will be met.
  • It is unclear how quickly meaningful outcome measures (for example, five-year survival rates) can be produced or compared, since survival metrics require long follow-up and the program is new.
  • The bill prevents removal of staff or funding reductions at certain Centers until 2030, which may limit VA flexibility to reallocate resources, but the bill does not explain how that interacts with overall VA budgets.
  • Some operational details are vague: the technical standards for the “uniform genetic sequencing platform,” criteria for selecting any additional Centers, exact eligibility rules for travel support, and how data privacy and sharing will be handled are not specified in the bill text.